Prime Medicine, Inc.
PRMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. At a $565.3M market cap, Prime Medicine, Inc. ranks as a small-cap company within healthcare. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Market Cap
$565.3M
Beta
2.27
P/E (TTM)
—
P/E (Fwd)
-3.72
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.84
ROE
-216.1%
ROA
-41.5%
Cash
$135.5M
Total Debt
$114.5M
Free CF
-$78.3M
52W Change
-24.2%
Annual Financials
Cash vs Debt
With $135.5M in cash and $114.5M in debt, PRME maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$78.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -216.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.27 means PRME is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Prime Medicine, Inc.'s trajectory.